Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Syantra
Related tests:


Syantra Announces Liquid Biopsy Platform Breakthrough with Expanded Intellectual Property Portfolio; Partnership with Limmi to Accelerate AI-Powered RNA-Based Early Cancer Detection Liquid Biopsy Program (Canada Newswire)
"Today, Syantra...announced additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease....The newly announced partnership with Limmi provides a scalable AI-powered platform to drive novel insights from clinical data and to ultimately enhance Syantra's ability to detect various cancers at early stages."
Licensing / partnership
Syantra receives CE Mark approval for their breast cancer test built on the Syantra DX™ liquid biopsy platform (Syantra Press Release)
"Syantra announced...that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat."
European regulatory
Syantra DX™ Breast Cancer test